

Annual Review of Pharmacology and Toxicology
**Environmental Obesogens:
 Mechanisms and Controversies**

Jerrold J. Heindel¹ and Bruce Blumberg²

¹Program on Endocrine Disruption Strategies, Commonweal, Bolinas, California 94924, USA

²Department of Developmental and Cell Biology, Department of Pharmaceutical Sciences, and Department of Biomedical Engineering, University of California, Irvine, California 92697, USA; email: blumberg@uci.edu

Annu. Rev. Pharmacol. Toxicol. 2019. 59:89–106

First published as a Review in Advance on
 July 25, 2018

The *Annual Review of Pharmacology and Toxicology*
 is online at pharmtox.annualreviews.org

<https://doi.org/10.1146/annurev-pharmtox-010818-021304>

Copyright © 2019 by Annual Reviews.
 All rights reserved

**ANNUAL
REVIEWS CONNECT**

www.annualreviews.org

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

Keywords

adipogenesis, BPA, DEHP, diabetes, DOHaD, EDC, metabolic syndrome, obesity, obesogen, TBT

Abstract

Obesity is a worldwide pandemic in adults as well as children and adds greatly to health care costs through its association with type 2 diabetes, metabolic syndrome, cardiovascular disease, and cancers. The prevailing medical view of obesity is that it results from a simple imbalance between caloric intake and energy expenditure. However, numerous other factors are important in the etiology of obesity. The obesogen hypothesis proposes that environmental chemicals termed obesogens promote obesity by acting to increase adipocyte commitment, differentiation, and size by altering metabolic set points or altering the hormonal regulation of appetite and satiety. Many obesogens are endocrine disrupting chemicals that interfere with normal endocrine regulation. Endocrine disrupting obesogens are abundant in our environment, used in everyday products from food packaging to fungicides. In this review, we explore the evidence supporting the obesogen hypothesis, as well as the gaps in our knowledge that are currently preventing a complete understanding of the extent to which obesogens contribute to the obesity pandemic.

INTRODUCTION

Obesity, defined as a body mass index (BMI) greater than 30 kg/m², is a global pandemic affecting children and adults in developing as well as developed countries (1). An extensive systematic review of the literature (encompassing more than 68 million people) revealed that in 2015, at least 1.9 billion adults aged 18 and older were overweight and approximately 650 million of these were obese (2, 3). Worldwide, 107.7 million children were obese (2). In many countries, the rate of increase in obesity in children is greater than in adults (2). Overweight or obesity accounted for 4 million deaths globally, with approximately 40% occurring in people who were overweight but not obese. Excess body weight accounted for 120 million disability-adjusted life years worldwide in 2015 (2). The prevalence of obesity in the United States more than doubled between 1980 and 2010, increasing from 13.4% to 35.7% (4). Overall obesity prevalence had increased to 37.7% by 2014 (5) and reached 39.8% by 2016 in the most recent analysis (6). Obesity disproportionately affects black (46.8%) and Hispanic (47.0%) populations, with an even stronger effect on black (54.8%) and Hispanic (50.6%) women (6). More than one-third of youth in the United States were overweight or obese in 2012 (7); the prevalence of obesity in youth was 18.5% in 2016, with the highest incidence in the oldest group (20.6% in ages 12–19 years) (6). Increased childhood obesity is strongly correlated with adult obesity and with increased diagnoses of type 2 diabetes in children and adolescents (8). Obesity and particularly increased visceral fat are recognized risk factors for metabolic syndrome, type 2 diabetes, and other metabolic diseases (9). Obesity is also linked with the incidence of cancer; nearly 40% of all cancers are diagnosed in overweight or obese people in the United States. (10). The additional cost of medical care attributable to obesity adds more than \$200 billion annually to the US health care budget (11). These excess costs derive from treating the many comorbidities of obesity, such as cardiovascular disease, dyslipidemia, type 2 diabetes, liver disease, neurodegenerative disease, cancers, and reproductive diseases (11–14).

CAUSES OF OBESITY

Disrupted Energy Balance Does Not Account for the Obesity Pandemic

For many years, the clinical paradigm for obesity has been a simple function of energy intake versus energy expenditure (15). Other well-studied risk factors implicated in obesity include genetics (16, 17), smoking during pregnancy (18, 19), stress (20, 21), the microbiome (22–24), and timing of meal consumption (25, 26), to name a few. The most prevalent clinical management strategies are focused on managing diet and increasing exercise (27). This myopic approach continues despite numerous studies demonstrating that exercise is consistently linked with increased fat mass in the long-term (28, 29). A recent analysis of data derived from the US National Health and Nutrition Examination Study (NHANES, 1971–2008) showed that leisure time physical activity increased 47% in males and 120% in females between 1988 and 2006, yet for an equivalent caloric intake, macronutrient intake, and leisure time physical activity, average adult BMI was up to 2.3 kg/m² higher in 2006 than in 1988 (30). Thus, decreased physical activity and increased food consumption are not adequate to explain the increase in BMI between 1988 and 2006 (30). These results cast serious doubt on the sufficiency of the simplistic energy balance model of obesity and strongly implicate the importance of other risk factors in obesity (30).

Multifactorial Nature of Obesity

Under normal conditions, the body typically autoregulates its weight; the brain senses and processes a variety of metabolic signals from several tissues and uses those data to control body

weight. Body weight in adults is typically stable over a long time, balancing metabolic and hedonic mechanisms (31). A return to normal weight quickly follows illness- or diet-induced weight loss. Similarly, a weight gain of 5–10 lbs as a result of dietary excess during a holiday season, for example, is quickly lost when individuals return to their normal life. Thus, the idea is emerging that body weight is regulated by a body weight set point (31). This idea is also supported by the observation that obesity is largely intractable once established. Multiple studies have reported that more than 83% of obese individuals who lost substantial amounts of weight through rigorous adherence to a strict regimen of dietary restriction and exercise gained it back within a few years (32–34). It is difficult to understand why such a small fraction of people who have successfully remodeled their bodies can sustain this substantial weight loss without invoking the concept of a body weight set point. How might such a set point be established?

Developmental Origin of Disease

Development is highly orchestrated and tightly controlled over time. The fetal origins hypothesis, first proposed by David Barker, posited that prenatal nutrition can play an important role in one's susceptibility to metabolic diseases and cardiovascular disorders later in life (35, 36). In this view, the type and amount of prenatal nutrition experienced by a fetus led to adaptation to the intrauterine nutritional environment. If the fetus experienced malnutrition in utero, as revealed by being born small for gestational age, Barker believed that the fetus had become adapted to a nutritionally poor environment. If the actual postnatal environment were not nutrient poor but rather nutritionally adequate or better, the child would be more susceptible to chronic diseases later in life, such as type 2 diabetes, high blood pressure, heart disease, and obesity due to this mismatch. Barker further posited that environmental factors acting during critical periods of development led to subsequent programming events that could influence physiology permanently, increasing susceptibility to diseases later in life (35, 36). He called this the thrifty phenotype that reflected early life programming as an altered ability to use and store calories later in life (36). Gluckman and Hanson (37–39) recognized that such critical periods were not restricted to fetal development and extended the fetal origins model, renaming it the developmental origins of health and disease (DOHaD) paradigm. The overall result of fetal and early life programming events is physiological function within normal parameters but with underlying functional deficits that can increase susceptibility to disease and dysfunction, particularly when other stressors such as diet are superimposed later in life. Studies in animals and humans have borne out a connection between poor prenatal nutrition and increased risk for diseases such as obesity throughout the life course and even in subsequent generations (35, 40). Despite considerable study, there are very few concrete details on the molecular mechanisms that promote a thrifty phenotype, although there are indications that leptin resistance (41) and epigenetic mechanisms are involved (42–44).

Obesity Begins in the Womb

As noted above, the obesity pandemic has also reached the pediatric population, where 18.5% of American children aged 2 to 19 were obese (≥ 95 th percentile on the Centers for Disease Control and Prevention growth charts), and 32% are overweight (≥ 85 th percentile) (6, 7). It is particularly alarming that obesity rates are also rising among children less than 2 years old (6). While an argument can be made that older children and adults might eat more and exercise less, it is difficult to argue that the typical infant now consumes more calories and exercises less than in previous generations. Therefore, it is more likely that the infant was born with more fat and/or that something about the early pre- and postnatal environments is different than in the past. Maternal nutrition

(35, 45), stress (46), and insulin state (47) have all been linked to risk of obesity in offspring, supporting the contention that aspects of the prenatal and early life environment play important roles in determining whether an individual may be predisposed to obesity and metabolic diseases later in life (48). With respect to the environment, a provocative study found that animals living near humans in industrialized societies have also exhibited pronounced increases in obesity over the past several decades (49). These animals included domestic cats and dogs (which one might suppose eat too much and exercise too little), feral rats living in cities, and crucially, six different species of laboratory animal models. The laboratory models included four different species of primates living in National Primate Research Centers as well as laboratory rats and mice, all living in environments where their diets are strictly controlled (49). Therefore, rather than ascribing this increased obesity to energy balance, a more reasonable inference is that something has changed about the environment in which these animals live that is making them obese in parallel with humans.

Endocrine Disrupting Chemicals

The endocrine system is known to play an important role in energy balance, fat deposition, and fat distribution in the body because many endocrine organs and hormones work together to regulate metabolism and body weight. Insulin and glucagon produced in the pancreas modulate glucose uptake and usage; ghrelin and cholecystokinin affect metabolism in the gastrointestinal tract; and glucagon, insulin, and fibroblast growth factor 21 (FGF21) act in the liver to control metabolism, hunger, and satiety. Sex hormones such as estradiol also contribute to energy metabolism and obesity by affecting food intake, body weight, and fat distribution and can alter the balance of glucose and insulin, lipogenesis, and lipolysis (reviewed in 48). The brain is an endocrine organ that both regulates metabolism and controls hedonic circuits that modulate food intake via reward mechanisms involving peptide hormones, neurotransmitters, and growth factors (31, 50–52).

An important advance in our understanding of how the environment can influence health, particularly by influencing developmental programming, came from the recognition that chemicals could disrupt function of the endocrine system (reviewed in 53, 54). The Endocrine Society defines an endocrine disrupting chemical (EDC) as an exogenous chemical, or mixture of chemicals, that can interfere with any aspect of hormone action (55). This is distinct from the toxicological definition of an EDC, which would add the rather vague requirement that such effects must be adverse. It is currently unclear how disrupting endocrine function would not be adverse per se, as is already widely recognized by endocrinologists and endocrine scientists (55).

The original definition of EDCs embodied in the Food Quality Protection Act of 1998 focused on estrogens, antiandrogens, and thyroid disruptors, but it is now recognized that any endocrine signaling system can be disrupted by exogenous chemicals that target different points in endocrine signaling pathways (54). For example, EDCs can affect how hormones are produced or destroyed and whether and how they might be transported through the blood and across cell membranes to their targets as well as modulate the molecular functions of specific hormone receptors and their cofactors (reviewed in 53, 54). In addition to the 48 nuclear hormone receptors encoded in the human genome, all of which are potential targets for being disrupted, there are hundreds of peptide hormone signaling pathways as well as a large number of receptors for as yet unidentified hormones. Thus, the potential for disrupting the action of endocrine hormones is considerable. However, why should our consideration of potential cellular targets of environmental chemicals be limited to endocrine hormones? Any receptor-based cellular signaling system can be disrupted by chemicals that act on the receptor. This leads to the concept of signal toxicity, wherein chemicals can act on any type of receptor and at any part of a cellular signaling pathway to disrupt cellular function (56). A key feature of this model is that rather than eliciting toxicity by damaging cellular

components, chemicals that cause signal toxicity do so by interfering with signaling itself (usually by acting on the receptor). A general feature of such cellular signaling systems is that molecules capable of disrupting them are expected to act at low doses (comparable to those of the endogenous hormones) and not to exhibit threshold effects, because the signaling systems are typically already active (57).

The Obesogen Hypothesis

In 2006, Grun & Blumberg (58) proposed the existence of EDCs that could influence adipogenesis and obesity and be important yet unsuspected players in the obesity epidemic. These obesogens are functionally defined as chemicals that promote obesity in humans or animals (58). The obesogen hypothesis further developed the DOHaD paradigm for obesity by proposing the existence of EDC obesogens that act during development to influence obesity later in life. Obesogens can act directly on cells to increase the commitment or differentiation of adipocytes from stem cells by altering the number of adipocytes, increasing storage of triglycerides into adipocytes, or altering the rate of adipocyte birth versus destruction. Obesogens can also act indirectly by changing basal metabolic rate, shifting energy balance to favor calorie storage, and modulating food intake and metabolism via effects on the brain, pancreas, adipose tissue, liver, gastrointestinal tract, and muscle (reviewed in 48, 59, 60). The effects of obesogens lead to an altered set point or sensitivity for developing obesity later in life (61, 62). This can exacerbate the effects of diet composition or caloric intake, making obesogens potential regulators of the body weight set point noted above. In this view, obesogens alone do not cause obesity in humans but can play an important behind-the-scenes role in weight gain due to developmental programming of the control of adipose tissue, food intake, and metabolism. Thus, obesogenic EDCs work by affecting nuclear factors or other endocrine pathways during development in ways that lead to obesity later in life.

Mechanisms of Obesogen Action

The interaction of multiple factors across the life span and generations makes it difficult to determine precisely to what extent exposure to EDC obesogens contributes to the obesity pandemic in humans, despite its great importance and interest to scientists, the public, and policy makers. To address this important question, one must examine the data that support or refute the obesogen hypothesis and the extent to which these data are consistent with the importance of environmental obesogens in the etiology of obesity. This topic has been extensively reviewed in both human and animal studies (48, 59, 60, 63–68). The reader is directed to these reviews for a more complete listing of chemicals shown or purported to be obesogens. Evidence has accumulated linking EDCs to obesity, and obesogens have been detected in humans (69–73) and animals (74–77). Because these chemicals are pervasive in the environment, it is crucial to understand how they disrupt developmental programming, predisposing individuals to obesity and related disorders. Although approximately 50 obesogens have been identified (48), there is little mechanistic understanding of how most function. Below, we briefly review the established mechanisms through which obesogens can act and give examples of chemicals acting through each.

Obesogens and the Programming of Adipocyte Development

One obesogen for which there is a considerable body of mechanistic evidence is tributyltin (TBT). TBT is widely used in industry and the related chemical triphenyltin (TPT) continues to be used in agriculture. Human exposure occurs through dietary sources such as seafood and shellfish

contaminated by TBT used in marine shipping applications or as fungicides for paper mills and industrial water systems. TPT use as a fungicide on high-value food crops presents more opportunities for human exposure. TBT contaminates plastics (e.g., polyvinyl chloride) and house dust (78, 79). TBT is a nanomolar affinity ligand that activates the master regulator of adipogenesis, peroxisome proliferator-activated receptor gamma (PPAR γ), and its heterodimeric partner, 9-*cis* retinoic acid receptor (RXR), to promote adipogenesis and alter lipid homeostasis (76, 80, 81). Human and mouse mesenchymal stem cells (MSCs) and preadipocytes are induced to differentiate into adipocytes via a PPAR γ -dependent pathway after exposure to TBT at environmentally relevant (nanomolar) levels or via PPAR γ agonists such as rosiglitazone (ROSI) (82–84). Adult mice exposed to TBT in utero displayed increased lipid accumulation in adipose depots, liver, and testis (76, 85). Although epidemiological studies of TBT levels and associated effects are scant, TBT continues to be found in house dust (79) and seafood (86), and at least one study shows increased ponderal index in human infants with the highest prenatal TBT exposure (87).

In vivo experiments identified several other chemicals as known obesogens. Exposure to the fungicides triflumizole (83) or tolylfluanid (88) or the plasticizer diethylhexyl phthalate (89) led to obesity later in life. Triflumizole was shown to act through PPAR γ (83), whereas tolylfluanid is thought to act via the glucocorticoid receptor (90). It is not known which receptor diethylhexyl phthalate acts through, but it may be PPAR γ .

Other potential obesogens have been identified that are known to act on preadipocytes or MSCs to promote adipogenic differentiation (91). TBT alters the genome-wide chromatin landscape by activating RXR to commit cells to the adipocyte lineage by decreasing the deposition of the repressive histone 3 lysine 27 trimethylation mark, leading to increased expression of genes favoring adipogenic commitment (92). Specific RXR activators (rexinoids) produce the same phenotype, so it is expected that other chemicals that activate RXR will increase adipogenic commitment in MSCs. Many potential obesogens, such as the agricultural chemicals quinoxifen and spirodiclofen, activate PPAR γ , whereas another, fludioxonil, activates RXR (91). The agrochemicals tebupirimfos, flusilazole, forchlorfenuron, acetamaprid, and pymetrozine induce 3T3-L1 preadipocytes to differentiate into adipocytes in culture by mechanisms other than activating PPAR γ (91). Flame retardants, phthalates, plasticizers, parabens, alkylphenols and bisphenols can all differentiate 3T3-L1 cells to adipocytes in vitro (reviewed in 48). It remains to be shown which of these chemicals are capable of inducing fat accumulation and obesity, in vivo, but one might reasonably expect that at least some will turn out to be bona fide obesogens.

Obesogens and Unhealthy Adipocytes

Considering how many chemicals increase the commitment or differentiation of adipocytes, it is reasonable to ask whether the adipocytes produced are normal and fully functional (93). White adipocytes are important in the maintenance of metabolic health by taking up glucose from the bloodstream in response to postprandial insulin (94). White adipose tissue (WAT) also has endocrine functions, releasing adipokines, such as adiponectin, that are important for metabolic health (95). Adiponectin expression suppresses gluconeogenesis and stimulates β -oxidation of fatty acids in the liver and is inversely correlated with risk of type 2 diabetes (96). PPAR γ activators are known to promote the development of healthy adipocytes (97, 98). Overall, functional adipocytes are characterized by their sensitivity to insulin, production of healthy adipokines such as adiponectin, and being small, normoxic cells that promote an anti-inflammatory and antifibrotic local microenvironment.

Sargis and colleagues (88) investigated functional differences in 3T3-L1 cells differentiated with TBT or the PPAR γ activator troglitazone. They found that the TBT-induced adipocytes

produced lower levels of adiponectin and CEBP α mRNA and protein, accompanied by reduced GLUT4 expression but normal glucose uptake and inferred that TBT had produced unhealthy adipocytes (88). Shoucri et al. (93) treated differentiating MSCs with TBT, ROSI, or the rexinoid IRX4204 and found that while TBT- and 4204-treated cells accumulated essentially the same amount of fat as did ROSI-treated cells, the TBT- and 4204-induced adipocytes were abnormal; that is, they did not express GLUT4 to levels comparable to ROSI, attenuating glucose uptake; showed reduced expression of adiponectin; and failed to downregulate the expression of markers of inflammation and fibrosis. The TBT- and 4204-treated cells also contained fewer mitochondria and did not respire at the rate achieved by ROSI-induced cells under stress (93). These cells were also impaired in their ability to produce thermogenic beige/brite fat as described in the next section. Overall, TBT- and rexinoid-differentiated adipocytes accumulated fat but did not respond to normal signaling processes. This may be relevant to the *in vivo* phenotypes where F4 generation male animals derived from TBT-treated F0 dams stored excess triglycerides when dietary fat was elevated and failed to mobilize this fat under fasting conditions (61). It is an open and important question whether other environmental obesogens generate normal or dysfunctional WAT.

Obesogens and Impaired Thermogenesis

A dimension of adipocyte function that has advanced greatly in recent years is the discovery that thermogenic brown adipose tissue (BAT) persists in adult humans and that WAT can be induced to produce thermogenic beige/brite fat (99, 100). This browning process produces thermogenic adipocytes that are characterized by abundant mitochondria. Expression of Uncoupling Protein 1 (UCP1) uncouples cellular respiration from ATP synthesis, producing heat instead of ATP. Thermogenic adipose tissue has important therapeutic potential as a treatment for obesity and diabetes since it readily converts blood glucose and fats into heat (101). Two lines of evidence suggest that some obesogens can act, in part, by impairing the function or differentiation of thermogenic fat. First, perinatal exposure to the insecticide dichlorodiphenyltrichloroethane (DDT) produces adult female rats that are intolerant to cold, exhibiting diminished energy expenditure and reduced core temperature (102). This phenotype of reduced BAT function resulted, in part, from diminished expression of a key regulator of BAT function, peroxisome proliferator-activated receptor γ coactivator 1 α (Ppargc1 α , or PGC-1 α) and iodothyronine deiodinase 2 (Dio2), which converts thyroxine (T4), to the more thermogenic triiodothyronine (T3). Second, Shoucri et al. (93) recently found that production of beige/brite fat cells from MSCs was inhibited by TBT or rexinoids. These examples indicate that obesogens can influence obesity by impairing thermogenesis, *in vivo*. This is an intriguing area for future study.

Obesogens and Altered Metabolic Set Points

Developmental obesogen exposure can result in increased fat depot weight as well as adipocyte size and number in animal models. The situation in humans is likely to be more complex with a number of contributing (genetics, diet, microbiome, circadian rhythms, exercise, environmental stressors) and confounding (prescription drugs, multiple exposures, individual variations) factors. As noted above, it is clear that in humans it is easy to gain weight, hard to lose weight, and even harder to maintain weight loss, all of which can be interpreted as indicative of the existence of a body weight set point. If true, this indicates that while food intake and exercise are very important factors in weight control, obesogen exposure can alter the amount of food needed to increase weight or the amount of exercise needed to lose weight by altering this set point. It may require a second hit in order to gain weight from obesogen exposure.

Several examples suffice to indicate the presence of a body weight set point that has been altered by obesogen exposure. Newbold et al. (103) showed that perinatal exposure to diethylstilbestrol led to weight gain at adulthood but not earlier. Developmental exposure to bisphenol A (BPA) throughout gestation and lactation in pregnant mice resulted in adult female animals that showed decreased activity and energy expenditure, although body weight and fat content were not assessed (104). Somm et al. (105) showed that prenatal nicotine exposure altered the body weight set point in rats such that less high-fat food was required to gain weight than in controls. Chamorro-Garcia et al. (61) showed that ancestral exposure to TBT led F4 male mice to gain weight very rapidly when dietary fat was increased and failed to mobilize this fat during fasting, likely as the result of leptin resistance. Lastly, a recent study on human diet-induced weight loss showed that while all subjects lost weight comparably when calories were restricted, those with the highest baseline plasma levels of perfluoroalkyl substances had lower resting metabolic rates and regained weight more rapidly (62). Taken together, these data strongly support the idea that obesogen exposure can alter body weight set points in multiple ways.

Transgenerational Effects

An important recent advance in the understanding of the effects of obesogens came with the finding that when pregnant mice were treated with environmentally relevant (nM) doses of TBT via their drinking water, effects were detected in the F1–F4 descendants of F0 mice exposed during pregnancy (85) or pregnancy and lactation (61). Unlike TBT, strong activators of PPAR γ such as ROSI could not elicit transgenerational effects on obesity (61, 85). TBT exposure led to a transgenerational thrifty phenotype in F4 male (but not female) mice. Males were resistant to fat loss during fasting, rapidly gained fat on a higher-fat diet, and retained this fat when returned to a low-fat diet. This was not simply a result of fat animals producing fat offspring, because the phenotype is not manifested until diet challenge. The thrifty phenotype was associated with changes in chromatin structure, DNA methylation, and overexpression of leptin and important metabolic genes in WAT (61). Thus, it was proposed that transgenerational obesity resulted from maternal programming leading to a heritable susceptibility.

Heritable effects of other chemicals on obesity have been demonstrated. Plastic components BPA and diethylhexyl and dibutyl phthalates (106), the pesticides methoxychlor (107) and DDT (109), and a mixed hydrocarbon jet fuel [Jet Propellant 8 (JP-8)] (108) all induced transgenerational obesity in rats. Two major arguments have been raised against the concept of epigenetic transgenerational inheritance. The first is that it presumes soma-to-germline transfer of heritable information, which is an anachronistic Lamarckian notion of inheritance and a violation of the Weismann barrier stating that hereditary information moves only from the germline to the soma (110). However, recent advances in developmental cell biology of germline genomics challenge Weismann's idea (111). Normal development of mammalian germline cells depends on hormonally regulated functions of somatic cells supporting their survival and differentiation. It is plausible that endocrine active substances may affect epigenetic reprogramming of germline cells. The second argument is that genome-wide epigenetic reprogramming in mammalian germline cells should erase epimutations from the preceding generation (110, 112, 113). While Skinner and colleagues (109, 114, 115) reported that vinclozolin exposure induces transgenerational changes in DNA methylation through the F3 and F4 generations, Szabó and colleagues (116) showed that vinclozolin-induced epimutations and alterations in gene expression are induced in the F1 generation but not conserved in F2 prospermatogonia. These contradictory results can be reconciled in a model proposed by Chamorro-Garcia et al. (61) positing that methylation at specific CpG sites does not need to be inherited, but rather changes in chromatin accessibility and/or organization

convey transgenerational traits. In this view, altered genomic structure and accessibility to epigenetic writing enzymes are inherited and these lead to regional changes in DNA methylation that occur in the areas of altered structure, leading to differential gene expression (61). It remains to be seen how many other EDCs or obesogens lead to transgenerational inheritance of obesity or other phenotypes.

WHAT CAN WE KNOW ABOUT THE ROLE OF OBESOGENS IN OBESITY?

As noted above, the etiology of obesity is multifactorial and cannot be linked specifically and wholly to one entity, including genetics or environmental chemicals. While dietary restriction and increased exercise continue to be the most prescribed remedies, the obesity pandemic continues unabated and is increasing worldwide (2). Despite the voluminous literature on obesogens and metabolism-disrupting chemicals (reviewed in 48), a series of workshops aimed at identifying the best evidence for obesogen effects on obesity and diabetes identified shortcomings in the existing body of evidence that has prevented a full and accurate analysis of the effects of many potential obesogens (14). What types of evidence will be required to overcome these shortcomings and firmly establish obesogens as important players in the obesity pandemic? What will be the best practices for human and animal studies? Below, we list some of these and follow with general conclusions and suggestions for future studies.

General Considerations

In addition to genetic background, stress, drugs, infections, diseases, and the microbiome, the effects of exposure to environmental chemicals will be specifically influenced by the following:

- The in utero period may be the most sensitive time of exposure, but our lack of understanding of all windows of sensitivity (which will differ by chemical) necessitates a developmental and life span approach.
- The window of sensitivity for an exposure to elicit a disease outcome may be longer than the time during which the exposure was assessed. This will require multiple exposure assessments over longer times, including preconception, early pregnancy, and early childhood.
- Some effects will be due to functional changes, perhaps epigenetic in nature, that will require sensitive and specific endpoints that might not become apparent until later in life, thus requiring a life span prospective approach.
- EDC and obesogen exposure typically occur at low levels that vary significantly over time, requiring multiple and sensitive measures of personal exposures.
- Multiple interacting exposures are typical, and individual sensitivities and half-lives of chemicals will differ, which requires mixture approaches and the use of appropriate statistical tools.
- Individuals will experience multiple hits over a lifetime, requiring a life span and statistical approach.
- Analysis of transgenerational effects will require biomarkers of ancestral exposure to identify who has been exposed.

Methodological Considerations in Epidemiological Studies

Epidemiological studies suggest a link between chemical exposures and a variety of health outcomes later in life, including obesity (reviewed in 117). However, results are often inconsistent across studies, which may be due to methodological challenges specific to epidemiology studies (reviewed

in 118, 119). A key challenge is to accurately estimate aggregate exposures to chemicals that may occur via multiple routes and have short half-lives resulting in concentrations that vary significantly over time. Potential misclassification of such exposures is particularly relevant for nonpersistent chemicals; interindividual variability both in exposures and in assessment must be addressed in the experimental design. Single-spot urine or even 24-h urine samples may be problematic as they only assess exposure over a day or even a part of a day (reviewed in 63, 119). For example, at least 10 and as many as 35 individual measurements may be needed to adequately assess individual BPA exposure (119, 120). It is also important to examine racial and ethnic differences in exposures (121). Exposure of humans to many potential EDCs can be confounded because most existing cohorts and epidemiological studies were designed to measure the impact of a single chemical without accounting for the effects of mixtures (63). Epidemiology studies must develop the appropriate statistical models to determine the health outcomes associated with specific chemicals in the mixture, and such models will need to deal with the fact that some EDCs act by the same mode and mechanism while interfering with others. Particular care must also be taken to avoid sample contamination during collection, handling, and storage, especially when assessing chemicals commonly associated with laboratories and medical equipment (e.g., phthalates and BPA).

It is also important that epidemiology studies assess the shape of the dose–response curve as some associations between exposures and health outcome may be nonmonotonic (57). Such studies should also consider the importance of determining chemical concentrations during the entire sensitive window of exposure, which may continue beyond in utero. Animal studies have revealed that obesogen effects on obesity are often sexually dimorphic; thus, epidemiological studies must consider both sexes and also overlapping endpoints that assess the function of multiple tissues and mechanisms.

In addition to all these challenges, it must be noted that in the absence of accidental or industrial exposures, epidemiological studies cannot definitively provide causal links between exposure and disease etiology. Thus, the most scientifically valid approach to determining the importance of EDC exposures to obesity is to focus on animal studies in which the study design can minimize effects of confounding variables and then assess links between exposures to such chemicals and the same disease outcomes in human cohorts.

Methodological Considerations in Animal Model Studies

While animal studies can provide important data linking obesogen exposure and obesity (that may show causality), important factors need to be addressed to assure a valid interpretable animal study. These include the following:

- Use a species and strain of animal known to be susceptible to the disease and ensure that the disease mimics the human disease. A model useful for a cancer study may not be appropriate for an obesity study.
- Assess endpoints that are sensitive and linked to the disease, not just body weight.
- Require the mandatory use of positive controls to ensure that the animal is responsive to the conditions of the study so that negative results can be taken as meaningful.
- Assess multiple, overlapping sensitive endpoints that evaluate multiple tissues and functions in both sexes.
- Use a wide variety of concentrations, including some that are in the range of human exposures (often below the NOAEL, or no observed adverse effect level), to determine whether effects are relevant to humans and may be nonmonotonic.

- Whenever possible, measure circulating levels of chemicals and metabolites to compare doses to human blood levels.
- Use sufficient numbers of animals per group for statistical significance.
- Randomize the animals, blind the animal groups to the researchers, and treat all groups in parallel to avoid batch effects.
- Use a diet containing protein, carbohydrates, phytoestrogens, and lipid concentrations that will allow obesity to manifest in the species studied.
- When using a high-fat diet, avoid the use of extremely high-fat diets (e.g., 60% kcal from fat) in favor of a diet that has modest levels of fat that can reveal effects while maintaining relevance to human biology.
- Dose during specific sensitive time periods that are appropriate to the purpose of the study, which could include a single or multiple exposure(s) within a generation or across generations.
- Use a route of exposure that fits the purpose of the study and is most relevant to human exposures. When alternative routes of exposure are required for the experiment, attempt to measure blood levels achieved and compare to oral dosing.

When assessing the results of animal studies, it is important to note that a positive result is more significant than a negative result since it is always possible to design an experiment that produces a negative outcome. It is also important to consider that it may not always be possible to perfectly replicate a study, due at least in part to local differences in microbiome composition. Therefore, even replicate studies may have different results. It is almost universally true that studies from diverse laboratories use different chemical doses, dosing periods, diets, housing conditions, and strains of animals. Accordingly, studies that do not report identical results do not necessarily disprove original positive or negative findings. It is also likely that different animal models may result in obesity via distinct mechanisms, including effects on diverse tissues. Moreover, it is important to note that there may be animal models, chemicals, and doses of specific chemicals that will not cause obesity per se but rather alter the set point for gaining weight. In such cases, a second hit may be needed, for example, a higher-fat diet. Since this is likely to be the human situation, these studies may be extremely relevant.

We argue that when assessing the preponderance of evidence from animal studies relevant to a particular hypothesis, all of the above considerations must be taken into account. It is insufficient to simply count the number of positive and negative studies and then infer whether a chemical can cause obesity.

Establishing a Causal Role for Obesogens in Obesity

The obesogen field is a bit more than a decade old. Over this first decade, the small cadre of scientists working on the role of EDCs in obesity has grown and the work has shown that there are obesogens, defined in animal studies, and they have the potential for effects in humans. Several international workshops have been held to discuss the potential role of EDCs in obesity and metabolic diseases (14, 48, 122, 123). There was wide agreement on the following points:

- The increase in obesity over the last 50+ years cannot be accounted for by genetic factors alone.
- Obesity has genetic, epigenetic, and environmental components.
- The environmental component is multifactorial and includes environmental chemicals.

- Susceptibility to obesity is at least in part programmed during development by broadly defined environmental factors, including stress, drugs, nutrition, microbiome, exercise, and environmental chemicals.
- Altered programming may affect brain appetite and satiety centers; fat cell number, size, and function; and muscle, gastrointestinal tract, pancreas, and liver.

The following points were estimated with confidence:

- Effects of obesogens are due to multiple hits across the life span and generations.
- Multiple, specific windows of enhanced sensitivity occur across the life span, including preconception, in utero, neonatal, prepuberty, and aging.
- The effects of obesogens are sexually dimorphic.
- Obesogens must be studied along with nutrition, activity, stress, infections, microbiome, and other factors to accurately assess the effects of environment on obesity.
- Some obesogens act transgenerationally, requiring a multigenerational approach.
- The current approach of testing one chemical at a time at one window of exposure is almost certainly underestimating the importance of obesogens.

FUTURE DIRECTIONS

There is an urgent, unmet need to understand the mechanisms underlying the predisposition to obesity and related disorders. Obesity currently adds more than \$200 billion to US health care costs annually, and the number of obese individuals continues to increase (6). Evidence implicating environmental influences on obesity is mounting, but the mechanisms of environmentally initiated obesity (i.e., other than by foods or lifestyles) remain largely unexplored. For example, while we and others showed that TBT exposure increased adiposity in mice, rats, and zebrafish, our recent study on the effects of altered diet on F4 male descendants of TBT-treated animals is among the first to test the interactions between diet composition and obesogen exposure (61). Thus, there is an important gap in our understanding of how current or ancestral obesogen exposure interacts with diet, an interaction that could be very significant for human health.

Effects of obesogen exposure on MSCs (84, 92) and on mice (61, 85) are likely to be epigenomic, yet little is known about the mechanisms responsible. How are effects of maternal exposure to obesogens transmitted to offspring and to subsequent generations? How does maternal exposure to TBT lead to a transgenerational thrifty phenotype (61)? And, how are perfluoroalkyl chemicals linked with reduced resting metabolic rate (62)? Which molecular targets mediate the effects of obesogens on metabolic programming, *in vivo*? A conservative estimate of the impact of three obesogens on the price of obesity in the European Union put the annual cost at €18 billion (14); a comparable study estimated the annual cost in the United States at \$5.9 billion (12). These estimates do not consider the extent to which exposure to organotins or any of the approximately 50 other obesogens impacts the human obesity epidemic, because there are an insufficient number of prospective cohort studies with multiple measurements of chemical exposure that can be linked with obesity, *in vivo*.

Relatively little is known about the extent to which obesogen exposure programs dysfunctional adipose tissue that may store but not mobilize fat. There is an extreme paucity of data on the effects of multiple or continuing exposures over the life course and across generations. Almost nothing is known about the extent to which obesogen exposure interacts with other established risk factors in obesity, such as inflammation, disrupted circadian rhythms, oxidative stress, mitochondrial dysfunction, dietary composition, timing of eating, and the regulation of appetite and satiety.

Perhaps most important, there is an almost complete lack of biomarkers of previous or ancestral obesogen exposure that can be assessed in the numerous existing human cohorts. Identifying these biomarkers will provide strong insights into the mechanisms underlying the effects of obesogen exposure, who has been exposed, and what links can be drawn among obesogen exposures, obesity, and metabolic diseases in the population.

DISCLOSURE STATEMENT

B.B. is a named inventor on US patents related to PPAR γ and other nuclear receptors. J.J.H. has received support from Commonweal.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health under grants ES023316 and ES021832 (to B.B.).

LITERATURE CITED

1. WHO (World Health Organ.). 2018. *Obesity and overweight*. Fact Sheet, World Health Organ., Geneva, Switz. <http://www.who.int/mediacentre/factsheets/fs311/en/>
2. GBD Obes. Collab., Afshin A, Forouzanfar MH, Reitsma MB, Sur P, et al. 2017. Health effects of overweight and obesity in 195 countries over 25 years. *N. Engl. J. Med.* 377:13–27
3. NCD Risk Factor Collab. 2016. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* 387:1377–96
4. Flegal KM, Carroll MD, Kit BK, Ogden CL. 2012. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA* 307:491–97
5. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. 2016. Trends in obesity among adults in the United States, 2005 to 2014. *JAMA* 315:2284–91
6. Hales C, Carroll M, Fryar CD, Ogden CL. 2017. *Prevalence of obesity among adults and youth: United States, 2015–2016*. NCHS Data Brief 288, US Dep. Health Hum. Serv., Hyattsville, MD
7. Ogden CL, Carroll MD, Kit BK, Flegal KM. 2014. Prevalence of childhood and adult obesity in the United States, 2011–2012. *JAMA* 311:806–14
8. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, et al. 2014. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA* 311:1778–86
9. Despres JP. 2012. Abdominal obesity and cardiovascular disease: Is inflammation the missing link? *Can. J. Cardiol.* 28:642–52
10. Steele C, Thomas C, Henley S, Massetti G, Galuska D, et al. 2017. Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005–2014. *MMWR Morb. Mortal. Wkly. Rep.* 66:1052–58
11. Cawley J, Meyerhoefer C. 2012. The medical care costs of obesity: an instrumental variables approach. *J. Health Econ.* 31:219–30
12. Attina TM, Hauser R, Sathyanarayana S, Hunt PA, Bourguignon JP, et al. 2016. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. *Lancet Diabetes Endocrinol.* 4:996–1003
13. Campbell JM, Lane M, Owens JA, Bakos HW. 2015. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. *Reprod. Biomed. Online* 31:593–604
14. Legler J, Fletcher T, Govarts E, Porta M, Blumberg B, et al. 2015. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. *J. Clin. Endocrinol. Metab.* 100:1278–88

15. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. 2012. Energy balance and its components: implications for body weight regulation. *Am. J. Clin. Nutr.* 95:989–94
16. Herbert A. 2008. The fat tail of obesity as told by the genome. *Curr. Opin. Clin. Nutr. Metab. Care* 11:366–70
17. Li S, Zhao JH, Luan J, Luben RN, Rodwell SA, et al. 2010. Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies. *Am. J. Clin. Nutr.* 91:184–90
18. Behl M, Rao D, Aagaard K, Davidson TL, Levin ED, et al. 2013. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: a national toxicology program workshop review. *Environ. Health Perspect.* 121:170–80
19. Power C, Jefferis BJ. 2002. Fetal environment and subsequent obesity: a study of maternal smoking. *Int. J. Epidemiol.* 31:413–19
20. Garruti G, Cotecchia S, Giampetruzzi F, Giorgino F, Giorgino R. 2008. Neuroendocrine deregulation of food intake, adipose tissue and the gastrointestinal system in obesity and metabolic syndrome. *J. Gastrointest. Liver. Dis.* 17:193–98
21. Torres SJ, Nowson CA. 2007. Relationship between stress, eating behavior, and obesity. *Nutrition* 23:887–94
22. Noble EE, Hsu TM, Jones RB, Fodor AA, Goran MI, Kanoski SE. 2017. Early-life sugar consumption affects the rat microbiome independently of obesity. *J. Nutr.* 147:20–28
23. Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, et al. 2016. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. *Genome. Med.* 8:67
24. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 444:1027–31
25. Garaulet M, Gomez-Abellan P. 2014. Timing of food intake and obesity: a novel association. *Physiol. Behav.* 134:44–50
26. Garaulet M, Gomez-Abellan P, Albuquerque-Bejar JJ, Lee YC, Ordovas JM, Scheer FA. 2013. Timing of food intake predicts weight loss effectiveness. *Int. J. Obes.* 37:604–11
27. Hill JO, Peters JC. 1998. Environmental contributions to the obesity epidemic. *Science* 280:1371–74
28. Melanson EL, Keadle SK, Donnelly JE, Braun B, King NA. 2013. Resistance to exercise-induced weight loss: compensatory behavioral adaptations. *Med. Sci. Sports Exerc.* 45:1600–9
29. Sawyer BJ, Bhammar DM, Angadi SS, Ryan DM, Ryder JR, et al. 2015. Predictors of fat mass changes in response to aerobic exercise training in women. *J. Strength Cond. Res.* 29:297–304
30. Brown RE, Sharma AM, Ardern CI, Mirdamadi P, Mirdamadi P, Kuk JL. 2016. Secular differences in the association between caloric intake, macronutrient intake, and physical activity with obesity. *Obes. Res. Clin. Pract.* 10:243–55
31. Yu Y-H, Vasselli JR, Zhang Y, Mechanick JI, Korner J, Peterli R. 2015. Metabolic versus hedonic obesity: a conceptual distinction and its clinical implications. *Obes. Rev.* 16:234–47
32. Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC. 2015. Probability of an obese person attaining normal body weight: cohort study using electronic health records. *Am. J. Public Health* 105:e54–59
33. Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, et al. 2016. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. *Obesity* 24:1612–19
34. Kraschewski JL, Boan J, Esposito J, Sherwood NE, Lehman EB, et al. 2010. Long-term weight loss maintenance in the United States. *Int. J. Obes.* 34:1644–54
35. Barker DJ. 2007. The origins of the developmental origins theory. *J. Intern. Med.* 261:412–17
36. Hales CN, Barker DJ. 2001. The thrifty phenotype hypothesis. *Br. Med. Bull.* 60:5–20
37. Gluckman PD, Hanson MA. 2004. Living with the past: evolution, development, and patterns of disease. *Science* 305:1733–36
38. Gluckman PD, Hanson MA, Bateson P, Beedle AS, Law CM, et al. 2009. Towards a new developmental synthesis: adaptive developmental plasticity and human disease. *Lancet* 373:1654–57
39. Hanson MA, Gluckman PD. 2015. Developmental origins of health and disease—global public health implications. *Best Pract. Res. Clin. Obstet. Gynaecol.* 29:24–31

40. Hanson M, Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD. 2011. Developmental plasticity and developmental origins of non-communicable disease: theoretical considerations and epigenetic mechanisms. *Prog. Biophys. Mol. Biol.* 106:272–80
41. Friedman J. 2014. 20 years of leptin: leptin at 20: an overview. *J. Endocrinol.* 223:T1–8
42. Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, et al. 2011. Epigenetic gene promoter methylation at birth is associated with child's later adiposity. *Diabetes* 60:1528–34
43. Lillycrop KA. 2011. Effect of maternal diet on the epigenome: implications for human metabolic disease. *Proc. Nutr. Soc.* 70:64–72
44. Barouki R, Melén E, Herceg Z, Beckers J, Chen J, et al. 2018. Epigenetics as a mechanism linking developmental exposures to long-term toxicity. *Environ. Int.* 114:77–86
45. Howie GJ, Sloboda DM, Kamal T, Vickers MH. 2009. Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. *J. Physiol.* 587:905–15
46. Entringer S, Wadhwa PD. 2013. Developmental programming of obesity and metabolic dysfunction: role of prenatal stress and stress biology. *Nestle Nutr. Inst. Workshop Ser.* 74:107–20
47. Simeoni U, Barker DJ. 2009. Offspring of diabetic pregnancy: long-term outcomes. *Semin. Fetal Neonatal Med.* 14:119–24
48. Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, et al. 2017. Metabolism disrupting chemicals and metabolic disorders. *Reprod. Toxicol.* 68:3–33
49. Klimentidis YC, Beasley TM, Lin HY, Murati G, Glass GE, et al. 2011. Canaries in the coal mine: a cross-species analysis of the plurality of obesity epidemics. *Proc. R. Soc. B* 278:1626–32
50. Jager G, Witkamp RF. 2014. The endocannabinoid system and appetite: relevance for food reward. *Nutr. Res. Rev.* 27:172–85
51. Schellekens H, Finger BC, Dinan TG, Cryan JF. 2012. Ghrelin signalling and obesity: at the interface of stress, mood and food reward. *Pharmacol. Ther.* 135:316–26
52. Volkow ND, Wang GJ, Tomasi D, Baler RD. 2013. Obesity and addiction: neurobiological overlaps. *Obes. Rev.* 14:2–18
53. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, et al. 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr. Rev.* 30:293–342
54. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, et al. 2015. EDC-2: the Endocrine Society's second scientific statement on endocrine-disrupting chemicals. *Endocr. Rev.* 36:E1–150
55. Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, et al. 2012. Endocrine-disrupting chemicals and public health protection: a statement of principles from the Endocrine Society. *Endocrinology* 153:4097–110
56. Kanno J. 2016. Introduction to the concept of signal toxicity. *J. Toxicol. Sci.* 41:SP105–9
57. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr., et al. 2012. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. *Endocr. Rev.* 33:378–455
58. Grun F, Blumberg B. 2006. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. *Endocrinology* 147:S50–55
59. Janesick A, Blumberg B. 2011. Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity. *Birth Defects Res. C. Embryo Today* 93:34–50
60. Janesick AS, Blumberg B. 2016. Obesogens: an emerging threat to public health. *Am. J. Obstet. Gynecol.* 214:559–65
61. Chamorro-Garcia R, Diaz-Castillo C, Shoucri BM, Kach H, Leavitt R, et al. 2017. Ancestral perinatal obesogen exposure results in a transgenerational thrifty phenotype in mice. *Nat. Commun.* 8:2012
62. Liu G, Dhana K, Furtado JD, Rood J, Zong G, et al. 2018. Perfluoroalkyl substances and changes in body weight and resting metabolic rate in response to weight-loss diets: a prospective study. *PLOS Med.* 15:e1002502
63. Braun JM, Gennings C, Hauser R, Webster TF. 2016. What can epidemiological studies tell us about the impact of chemical mixtures on human health? *Environ. Health Perspect.* 124:A6–9
64. Darbre PD. 2017. Endocrine disruptors and obesity. *Curr. Obes. Rep.* 6:18–27
65. Janesick AS, Schug TT, Heindel JJ, Blumberg B. 2014. Environmental chemicals and obesity. In *Handbook of Obesity: Epidemiology, Etiology, and Physiopathology*, Vol. 1, ed. GA Bray, C Bouchard, pp. 471–88. Boca Raton, FL: CRC. 3rd ed.

66. Le Magueresse-Battistoni B, Labaronne E, Vidal H, Naville D. 2017. Endocrine disrupting chemicals in mixture and obesity, diabetes and related metabolic disorders. *World J. Biol. Chem.* 8:108–19
67. Stegemann R, Buchner DA. 2015. Transgenerational inheritance of metabolic disease. *Semin. Cell Dev. Biol.* 43:131–40
68. Stojanoska MM, Milosevic N, Milic N, Abenavoli L. 2017. The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders. *Endocrine* 55:666–81
69. Stahlhut RW, van Wijgaarden E, Dye TD, Cook S, Swan SH. 2007. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. *Environ. Health Perspect.* 115:876–82
70. Hatch EE, Nelson JW, Qureshi MM, Weinberg J, Moore LL, et al. 2008. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. *Environ. Health* 7:27
71. Trasande L, Attina TM, Blustein J. 2012. Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. *JAMA* 308:1113–21
72. Li DK, Miao M, Zhou Z, Wu C, Shi H, et al. 2013. Urine bisphenol-A level in relation to obesity and overweight in school-age children. *PLOS ONE* 8:e65399
73. Tang-Peronard JL, Andersen HR, Jensen TK, Heitmann BL. 2011. Endocrine-disrupting chemicals and obesity development in humans: a review. *Obes. Rev.* 12:622–36
74. Newbold RR, Padilla-Banks E, Jefferson WN. 2009. Environmental estrogens and obesity. *Mol. Cell Endocrinol.* 304:84–89
75. Vom Saal FS, Nagel SC, Coe BL, Angle BM, Taylor JA. 2012. The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity. *Mol. Cell Endocrinol.* 354:74–84
76. Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, et al. 2006. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. *Mol. Endocrinol.* 20:2141–55
77. Hines EP, White SS, Stanko JP, Gibbs-Flournoy EA, Lau C, Fenton SE. 2009. Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: low doses induce elevated serum leptin and insulin, and overweight in mid-life. *Mol. Cell Endocrinol.* 304:97–105
78. Fromme H, Mattulat A, Lahrz T, Ruden H. 2005. Occurrence of organotin compounds in house dust in Berlin (Germany). *Chemosphere* 58:1377–83
79. Kannan K, Takahashi S, Fujiwara N, Mizukawa H, Tanabe S. 2010. Organotin compounds, including butyltins and octyltins, in house dust from Albany, New York, USA. *Arch. Environ. Contam. Toxicol.* 58:901–7
80. le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, et al. 2009. Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. *EMBO Rep.* 10:367–73
81. Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa J. 2005. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. *Mol. Pharmacol.* 67:766–74
82. Li X, Ycaza J, Blumberg B. 2011. The environmental obesogen tributyltin chloride acts via peroxisome proliferator activated receptor gamma to induce adipogenesis in murine 3T3-L1 preadipocytes. *J. Steroid. Biochem. Mol. Biol.* 127:9–15
83. Li X, Pham HT, Janesick AS, Blumberg B. 2012. Triflumizole is an obesogen in mice that acts through peroxisome proliferator activated receptor gamma (PPAR γ). *Environ. Health Perspect.* 120:1720–26
84. Kirchner S, Kieu T, Chow C, Casey S, Blumberg B. 2010. Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. *Mol. Endocrinol.* 24:526–39
85. Chamorro-Garcia R, Sahu M, Abbey RJ, Laude J, Pham N, Blumberg B. 2013. Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice. *Environ. Health Perspect.* 121:359–66
86. Mattos Y, Stotz WB, Romero MS, Bravo M, Fillmann G, Castro IB. 2017. Butyltin contamination in Northern Chilean coast: Is there a potential risk for consumers? *Sci. Total Environ.* 595:209–17
87. Rantakokko P, Main KM, Wohlfart-Veje C, Kiviranta H, Airaksinen R, et al. 2014. Association of placenta organotin concentrations with growth and ponderal index in 110 newborn boys from Finland during the first 18 months of life: a cohort study. *Environ. Health* 13:45

88. Regnier SM, El-Hashani E, Kamau W, Zhang X, Massad NL, Sargis RM. 2015. Tributyltin differentially promotes development of a phenotypically distinct adipocyte. *Obesity* 23:1864–71
89. Hao C, Cheng X, Guo J, Xia H, Ma X. 2013. Perinatal exposure to diethyl-hexyl-phthalate induces obesity in mice. *Front. Biosci.* 5:725–33
90. Regnier SM, Kirkley AG, Ye H, El-Hashani E, Zhang X, et al. 2015. Dietary exposure to the endocrine disruptor tolylfluanid promotes global metabolic dysfunction in male mice. *Endocrinology* 156:896–910
91. Janesick AS, Dimastrogiovanni G, Vanek L, Boulos C, Chamorro-Garcia R, et al. 2016. On the utility of ToxCast and ToxPi as methods for identifying new obesogens. *Environ. Health Perspect.* 124:1214–26
92. Shoucri BM, Martinez ES, Abreo TJ, Hung VT, Moosova Z, et al. 2017. Retinoid X receptor activation alters the chromatin landscape to commit mesenchymal stem cells to the adipose lineage. *Endocrinology* 158:3109–25
93. Shoucri BM, Hung VT, Chamorro-García R, Shioda T, Blumberg B. 2018. Retinoid X receptor activation during adipogenesis programs. 1. A dysfunctional adipocyte. *Endocrinology* 159:2863–83
94. Satiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 414:799–806
95. Ouchi N, Parker JL, Lugus JJ, Walsh K. 2011. Adipokines in inflammation and metabolic disease. *Nat. Rev. Immunol.* 11:85–97
96. Li S, Shin HJ, Ding EL, van Dam RM. 2009. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 302:179–88
97. Kusminski CM, Bickel PE, Scherer PE. 2016. Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nat. Rev. Drug. Discov.* 15:639–60
98. Sun K, Tordjman J, Clément K, Scherer PE. 2013. Fibrosis and adipose tissue dysfunction. *Cell Metab.* 18:470–77
99. Nam M, Cooper MP. 2015. Role of energy metabolism in the brown fat gene program. *Front. Endocrinol.* 6:104
100. Kajimura S, Saito M. 2014. A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. *Annu. Rev. Physiol.* 76:225–49
101. Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. 2015. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. *Front. Physiol.* 6:4
102. La Merrill M, Karey E, Moshier E, Lindtner C, La Frano MR, et al. 2014. Perinatal exposure of mice to the pesticide DDT impairs energy expenditure and metabolism in adult female offspring. *PLOS ONE* 9:e103337
103. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. 2005. Developmental exposure to estrogenic compounds and obesity. *Birth Defects Res. A* 73:478–80
104. Johnson SA, Painter MS, Javurek AB, Ellersieck MR, Wiedmeyer CE, et al. 2015. Sex-dependent effects of developmental exposure to bisphenol A and ethinyl estradiol on metabolic parameters and voluntary physical activity. *J. Dev. Orig. Health Dis.* 6:539–52
105. Somm E, Schwitzgebel VM, Toulotte A, Cederroth CR, Combescure C, et al. 2009. Perinatal exposure to bisphenol A alters early adipogenesis in the rat. *Environ. Health Perspect.* 117:1549–55
106. Manikkam M, Tracey R, Guerrero-Bosagna C, Skinner MK. 2013. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. *PLOS ONE* 8:e55387
107. Manikkam M, Haque MM, Guerrero-Bosagna C, Nilsson EE, Skinner MK. 2014. Pesticide methoxychlor promotes the epigenetic transgenerational inheritance of adult-onset disease through the female germline. *PLOS ONE* 9:e102091
108. Tracey R, Manikkam M, Guerrero-Bosagna C, Skinner MK. 2013. Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. *Reprod. Toxicol.* 36:104–16
109. Skinner MK, Manikkam M, Tracey R, Guerrero-Bosagna C, Haque M, Nilsson EE. 2013. Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epigenetic transgenerational inheritance of obesity. *BMC Med.* 11:228
110. Whitelaw E. 2015. Disputing Lamarckian epigenetic inheritance in mammals. *Genome Biol.* 16:60

111. Surani MA. 2016. Breaking the germ line–soma barrier. *Nat. Rev. Mol. Cell Biol.* 17:136
112. Franklin TB, Mansuy IM. 2010. Epigenetic inheritance in mammals: evidence for the impact of adverse environmental effects. *Neurobiol. Dis.* 39:61–65
113. Heard E, Martienssen RA. 2014. Transgenerational epigenetic inheritance: myths and mechanisms. *Cell* 157:95–109
114. Skinner MK, Guerrero-Bosagna C, Haque MM. 2015. Environmentally induced epigenetic transgenerational inheritance of sperm epimutations promote genetic mutations. *Epigenetics* 10:762–71
115. Haque MM, Nilsson EE, Holder LB, Skinner MK. 2016. Genomic clustering of differential DNA methylated regions (epimutations) associated with the epigenetic transgenerational inheritance of disease and phenotypic variation. *BMC Genom.* 17:418
116. Iqbal K, Tran DA, Li AX, Warden C, Bai AY, et al. 2015. Deleterious effects of endocrine disruptors are corrected in the mammalian germline by epigenome reprogramming. *Genome. Biol.* 16:59
117. Heindel JJ, Skalla LA, Joubert BR, Dilworth CH, Gray KA. 2017. Review of developmental origins of health and disease publications in environmental epidemiology. *Reprod. Toxicol.* 68:34–48
118. Braun JM. 2017. Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. *Nat. Rev. Endocrinol.* 13:161–73
119. Braun JM, Gray K. 2017. Challenges to studying the health effects of early life environmental chemical exposures on children’s health. *PLOS Biol.* 15:e2002800
120. Perrier F, Giorgis-Allemand L, Slama R, Philippat C. 2016. Within-subject pooling of biological samples to reduce exposure misclassification in biomarker-based studies. *Epidemiology* 27:378–88
121. Zota AR, Shamasunder B. 2017. The environmental injustice of beauty: framing chemical exposures from beauty products as a health disparities concern. *Am. J. Obstet. Gynecol.* 217:418.e1–e6
122. Heindel JJ, vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, et al. 2015. Parma consensus statement on metabolic disruptors. *Environ. Health* 14:54
123. Lind L, Lind PM, Lejonklou MH, Dunder L, Bergman A, et al. 2016. Uppsala consensus statement on environmental contaminants and the global obesity epidemic. *Environ. Health Perspect.* 124:A81–83



Contents

Role of Cell Death in Toxicology: Does It Matter How Cells Die? <i>Sten Orrenius</i>	1
Introduction to the Theme “New Therapeutic Targets” <i>Paul A. Insel, Susan G. Amara, Terrence F. Blaschke, and Urs A. Meyer</i>	15
Systems Pharmacology: Defining the Interactions of Drug Combinations <i>J.G. Coen van Hasselt and Ravi Iyengar</i>	21
Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials <i>Ravi B. Patel and Sanjiv J. Shah</i>	41
Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes <i>Leigh Goedeke, Rachel J. Perry, and Gerald I. Shulman</i>	65
Environmental Obesogens: Mechanisms and Controversies <i>Jerrold J. Heindel and Bruce Blumberg</i>	89
The Exposome: Molecules to Populations <i>Megan M. Niedzwiecki, Douglas I. Walker, Roel Vermeulen, Marc Chadeau-Hyam, Dean P. Jones, and Gary W. Miller</i>	107
Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy <i>Terry J. Smith</i>	129
Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders <i>Jerold Chun, Yasuyuki Kihara, Deepa Jonnalagadda, and Victoria A. Blabo</i>	149
The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder <i>Chadi G. Abdallah, Lynnette A. Averill, Teddy J. Akiki, Mohsin Raza, Christopher L. Averill, Hassaan Gomaa, Archana Adikey, and John H. Krystal</i>	171

The Placebo Effect in Pain Therapies <i>Luana Colloca</i>	191
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants <i>Todd D. Gould, Carlos A. Zarate Jr., and Scott M. Thompson</i>	213
Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation <i>Miguel Moutinho, Juan F. Codocedo, Shweta S. Puntambekar, and Gary E. Landreth</i>	237
The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease <i>Birgit Liss and Jörg Striessnig</i>	263
Therapeutic Approaches to the Treatment of Tinnitus <i>Berthold Langguth, Ana Belen Elgoyben, and Christopher R. Cederroth</i>	291
Muscle Wasting Diseases: Novel Targets and Treatments <i>Regula Furrer and Christoph Handschin</i>	315
Novel Clinical Toxicology and Pharmacology of Organophosphorus Insecticide Self-Poisoning <i>Michael Eddleston</i>	341
New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy <i>Masanori Kawakami, Xi Liu, and Ethan Dmitrovsky</i>	361
Pharmacologic Targeting of Hypoxia-Inducible Factors <i>Gregg L. Semenza</i>	379
Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries <i>Marcus C. Parrish, Yuan Jin Tan, Kevin V. Grimes, and Daria Mochly-Rosen</i>	405
Moving from the Trial to the Real World: Improving Medication Adherence Using Insights of Implementation Science <i>Leab L. Zullig, Mieke Deschodt, Jan Liska, Hayden B. Bosworth, and Sabina De Geest</i>	423
Organoids for Drug Discovery and Personalized Medicine <i>Toshio Takahashi</i>	447
Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions <i>Jason H. Karnes, Matthew A. Miller, Katie D. White, Katherine C. Konvinse, Rebecca K. Pavlos, Alec J. Redwood, Jonathan G. Peter, Rannakoe Lebloenya, Simon A. Mallal, and Elizabeth J. Phillips</i>	463

Recent Developments in Understanding Barrier Mechanisms in the Developing Brain: Drugs and Drug Transporters in Pregnancy, Susceptibility or Protection in the Fetal Brain? <i>Norman R. Saunders, Katarzyna M. Dziegielewska, Kjeld Møllgård, and Mark D. Habgood</i>	487
Assessment of Pharmacokinetic Drug–Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited <i>Uwe Fuhr, Chih-bsuan Hsin, Xia Li, Wafaâ Jabrane, and Fritz Sörgel</i>	507
Metals and Mechanisms of Carcinogenesis <i>Qiao Yi Chen, Thomas DesMarais, and Max Costa</i>	537
Modulating NRF2 in Disease: Timing Is Everything <i>Matthew Dodson, Montserrat Rojo de la Vega, Aram B. Cholanians, Cody J. Schmidlin, Eli Chapman, and Donna D. Zhang</i>	555
Cardiovascular Pharmacogenomics: Does It Matter If You’re Black or White? <i>Tanima De, C. Sebwani Park, and Minoli A. Perera</i>	577
Therapeutic Oligonucleotides: State of the Art <i>C.I. Edvard Smith and Rula Zain</i>	605

Indexes

Cumulative Index of Contributing Authors, Volumes 55–59	631
Cumulative Index of Article Titles, Volumes 55–59	635

Errata

An online log of corrections to *Annual Review of Pharmacology and Toxicology* articles may be found at <http://www.annualreviews.org/errata/pharmtox>